Biological Drug API Manufacturing Services World Industry and Market Predictions 2017-2027

LONDON, August 14, 2017 /PRNewswire/ --

Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine

The Biological Drug API Manufacturing Services World Industry and Market Predictions 2017-2027: Analysis and Forecasts for Mammalian Cell Cultures, Microbial Fermentations, Other Expression Systems, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines and Geography report reviews the contract active pharmaceutical ingredient (API) manufacturing market for biologics. This study gives quantitative and qualitative analysis for that overall world market, as well as for countries and other submarkets, including the mammalian cell culture and microbial fermentation segments. This report assesses leading applications and significant developments within each, as well as drivers and restraints for them. Future trends that will affect the biotech API manufacturing services market are also examined. In addition, this study profiles leading contract manufacturing organisations (CMOs) in the outsourcing market and assesses their outlooks. Visiongain provides forecasts revenues for the period 2016 to 2027 for the biotech API manufacturing services market, as well as for therapeutic applications.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this 227 page report delivers:  

• Provides qualitative and quantitative analysis of the leading submarkets the period 2017-2027. Visiongain forecasts revenues and their growth for these submarkets:
- Mammalian cell culture
- Microbial fermentation
- Other expression platforms

• Provides qualitative and quantitative analysis of the leading contract API biological drug applications for the period 2017-2027. Visiongain forecasts contract API drug revenues to 2027 for these individual segments:
- Monoclonal antibody (mAb) therapies
- Vaccines
- Insulin therapies
- Interferon therapies
- Growth hormones.

• Find forecasts of the leading therapeutic and national markets from 2016 to 2027:
- The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
- The US
- Japan
- Switzerland
- Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore.

• Profiles leading global and national companies that offer biotech API manufacturing services to the pharmaceutical industry. For each company, current services offered, recent developments and outlooks are discussed. Leading CMOs profiled in this chapter are:
- Boehringer Ingelheim BioXcellence
- Celltrion
- DSM Biologics
- Lonza
- Samsung BioLogics
- Cytovance Biologics
- Fujifilm Diosynth Biotechnologies
- Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.

• Discover the regulatory outlook for biotech API manufacturing in leading regional and national markets in 2017, as well as predicted developments for the period to 2027.

• Identify important drug development and technology trends that will affect CMOs, their clients and other market participants from 2017. The report also contains SWOT and STEP analysis of the industry and market.

• Find profiles for leading CMOs offering biological drug API manufacturing services to pharmaceutical companies.

To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100

Or click on  https://www.visiongain.com/Report/1953/Biological-Drug-API-Manufacturing-Services-World-Industry-and-Market-Predictions-2017-2027

List of Companies:

Abasria

AbbVie

Accord Healthcare

Acquired Cedarburg Pharmaceuticals,

Actavis Generics

Adaptimmune Therapeutics

Agensys

Althera Technologies

Altus Pharmaceuticals

Amgen

Apotex

Aptuit

arGEN-X

Ascendis Pharma A/S

Asterion

Astra Zeneca

Avid Bioservices Inc

Bakhu Pharma.

Banner Life Sciences

Basaglar

Baxalta 

Baxter

Bayer

Bever Pharmaceutical

Biocad

Biocon

Biogen

Biogen Idec

BMS

Boehringer Ingelheim

Boehringer Ingelheim BioXcellence

Bolder BioTechnology

Calico Life Science

Caspugel

Catalent Biologics

Celgene

Celldex Therapautics

Celltrion

Cinfa

CMC Biologics

CMIC Holdings Co. Ltd.

CMO Relthy Laboratórios

Cook Pharmica

Critical Pharmaceuticals

CT Arzneimittel

Cytos Biotechnology

Cytovance Biologics

DPx Fine Chemicals

DPx Holdings B.V.

DSM Biologics

DSM Sinochem Pharmaceuticals

Eli Lily

EMD Millipore

EMD Millipore

Ferring Pharmaceuticals

Filnox Biotech

Fresenius

Fujifilm Diosynth Biotechnologies

Gallus BioPharmaceuticals,

GE Healthcare

Genentech

GeneScience Pharmaceuticals Co., Ltd.

Genexine and Handok

Genmab

Genzyme

Gilead Sciences, Inc.

GSK

Hanmi Pharmaceutical Co.

Hexal

Index Ventures

Infarco

Infinity Pharmaceuticals

Inno Biologics

Innovation Network Corporation of Japan (INCJ),

Johnson and Johnson

Johnson Matthey

JSR Corporation

Kalon Bio

Kalon Bio therapeutics

KBI Biopharma, Inc.

Kemwell

Kyowa Hakko Kirin

Labrys Biologics Inc,

Laureate Biopharma

LG Life Sciences, Ltd.

Lonza

Matrix Laboratories

Merck

Mitsubishi Gas Chemical Company

Mylan

Neopharm

Nikon

Nippon kayaku

Norbitec

Novartis

Novasep

Novo Nordisk

Nuron Biotech

Nycomed

OPKO Biologics and Pfizer

Opko Health

Patheon

PelChem

Peregrine Pharmaceuticals

Perrigo

Pfizer

Pharmstandard

Phyton Biotech

Piramal Healthcare

Precision Biologics

Progenics

Quintiles

Rebtschler Biotechnologie

Recepta Biopharma

Redwood Bioscience

Rentschler

Rentschler Biotechnologie

Roche

RoYal DSM

SAFC

Samsung BioLogics

Sanofi

SCM Pharma

Seattle Genetics

ShangPharma

SICOR Biotech

Sigma-Aldrich Corporation

Stada

SunShine Biopharma

SynCo BioPartners

Takeda

Teva

Therapure Biopharma

Thermo Fisher

Toyobo Biologics

Transgene SA

Versartis

Vertex

Vida Pharma

VTU

WuXi Biologics,

WuXi PharmaTech

Zhangjiang Biotech

Zhejiang Jiang Yuan Tang Biotechnology

ZJ Base

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain Ltd